Cubist Systematic Strategies’s Trillium Therapeutics Inc. TRIL Stock Holding History

Cubist Systematic Strategies’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-41,816	Closed	-$734K	–	3763
2021 Q3	$734K	Buy	+41,816	New	+$489K	0.01%	1761
2021 Q2	–	Sell	-11,972	Closed	-$128K	–	3211
2021 Q1	$128K	Buy	11,972 +4,172	+53%	+$51.6K	﹤0.01%	2596
2020 Q4	$115K	Sell	7,800 -216,156	-97%	-$3.12M	﹤0.01%	2386
2020 Q3	$3.18M	Buy	223,956 +145,057	+184%	+$1.45M	0.05%	627
2020 Q2	$638K	Buy	78,899 +72,590	+1,151%	+$449K	0.01%	1459
2020 Q1	$25K	Buy	+6,309	New	+$23.8K	﹤0.01%	2055

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Cubist Systematic Strategies's TRIL Position: Q4 2021 in Review

Cubist Systematic Strategies sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 41,816 shares — an estimated $734K sold.

Cubist Systematic Strategies first reported a position in TRIL in Q1 2020 and held it in 6 quarters. The position peaked at $3.18M in Q3 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Cubist Systematic Strategies reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Cubist Systematic Strategies sold 41,816 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $734K.
Cubist Systematic Strategies first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 6 quarters.
Cubist Systematic Strategies's Trillium Therapeutics Inc. position peaked at $3.18M in Q3 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Cubist Systematic Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.